EP
CRSP icon

Essential Partners’s CRISPR Therapeutics CRSP Stock Holding History

Essential Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$327 Sell
6
-65
-92% -$3.43K ﹤0.01% 2553
2026
Q1 		$3.38K Hold
71
– – ﹤0.01% 1764
2025
Q4 		$3.72K Sell
71
-1
-1% -$60 ﹤0.01% 1547
2025
Q3 		$4.67K Buy
72
+1
+1% +$57 ﹤0.01% 1452
2025
Q2 		$3.45K Buy
+71
New +$2.75K ﹤0.01% 1155

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Essential Partners's CRSP Position: Q2 2026 in Review

Essential Partners reduced its CRISPR Therapeutics (CRSP) stake by 92% in Q2 2026, selling an estimated $3.43K and leaving 6 shares worth $327. The position accounts for ﹤0.01% of the portfolio, ranked #2553.

Essential Partners first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.67K in Q3 2025. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Essential Partners held 6 shares of CRISPR Therapeutics worth $327 as of Q2 2026.
  • Essential Partners sold 65 CRISPR Therapeutics shares in Q2 2026, an estimated $3.43K.
  • CRISPR Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2553 holding.
  • Essential Partners first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's CRISPR Therapeutics position peaked at $4.67K in Q3 2025.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.